Grifols SA
Company Profile
Business description
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Contact
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935710500
E: investors@grifols.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,822
Stocks News & Analysis
stocks
6 undervalued stocks with low beta
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,631.50 | 42.70 | 0.50% |
| CAC 40 | 7,826.79 | 1.34 | -0.02% |
| DAX 40 | 24,226.49 | 198.84 | 0.83% |
| Dow JONES (US) | 42,343.65 | 740.58 | 1.78% |
| FTSE 100 | 8,778.05 | 60.08 | 0.69% |
| HKSE | 23,381.99 | 99.66 | 0.43% |
| NASDAQ | 19,199.16 | 461.96 | 2.47% |
| Nikkei 225 | 37,724.11 | 192.58 | 0.51% |
| NZX 50 Index | 12,531.30 | 51.03 | -0.41% |
| S&P 500 | 5,921.54 | 118.72 | 2.05% |
| S&P/ASX 200 | 8,407.60 | 46.60 | 0.56% |
| SSE Composite Index | 3,340.69 | 6.15 | -0.18% |